An update on antibody-based immunotherapies for Clostridium difficile infection

Download
  1. (PDF, 897 KB)
  2. Get@NRC: An update on antibody-based immunotherapies for Clostridium difficile infection (Opens in a new window)
DOIResolve DOI: http://doi.org/10.2147/CEG.S84017
AuthorSearch for: ; Search for:
TypeArticle
Journal titleClinical and Experimental Gastroenterology
ISSN1178-7023
1178-7023
Volume9
Pages209224
Subjectantibody; Clostridium difficile; immunotherapy; toxin
AbstractClostridium difficile continues to be one of the most prevalent hospital-acquired bacterial infections in the developed world, despite the recent introduction of a novel and effective antibiotic agent (fidaxomicin). Alternative approaches under investigation to combat the anaerobic Gram-positive bacteria include fecal transplantation therapy, vaccines, and antibody-based immunotherapies. In this review, we catalog the recent advances in antibody-based approaches under development and in the clinic for the treatment of C. difficile infection. By and large, inhibitory antibodies that recognize the primary C. difficile virulence factors, toxin A and toxin B, are the most popular passive immunotherapies under investigation. We provide a detailed summary of the toxin epitopes recognized by various antitoxin antibodies and discuss general trends on toxin inhibition efficacy. In addition, antibodies to other C. difficile targets, such as surface-layer proteins, binary toxin, motility factors, and adherence and colonization factors, are introduced in this review.
Publication date
PublisherDove Medical Press
LanguageEnglish
AffiliationHuman Health Therapeutics; National Research Council Canada
Peer reviewedYes
NPARC number23000647
Export citationExport as RIS
Report a correctionReport a correction
Record identifiercb331245-37fb-4216-864c-5b5e832a8377
Record created2016-08-17
Record modified2016-08-17
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)